Phoenix Biotechnology, Inc. (PBI)'s Focus
Phoenix Biotechnology, Inc., has been exploring the health-related benefits of a novel extract of Nerium oleander for the past 20 years. The company has developed a supercritical CO2 extraction of Nerium oleander into a new botanical drug – PBI-05204.
PBI-05204 is a ‘botanical drug’ that has been through initial FDA review and approved for the Phase I and Phase II clinical trials which were conducted in the United States. These trials have shown that this oral (capsule) formulation is safe for administration to patients without undue toxicity.
A distinction of PBI-05204 is that research has consistently proven that this drug crosses the blood brain barrier which opens up several potential applications. Extensive research has been done in the following areas: Antiviral, Cancer, and Neurodegenerative Diseases.
“Antiviral Effects of Oleandrin". Newman RA, Sastry KJ, Arav-Boger R, Cai H, Matos R, Harrod R. J Exp Pharmacol. 2020;12:503-515
This review article demonstrates clearly that oleandrin is effective against a wide variety of viruses including SARS-CoV-2. The cited research was reported not only by PBI scientists but many other investigators from institutions around the world.
“The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal Properties". Colapietro Alessandro, Yang Peiying, Rossetti Alessandra, Mancini Andrea, Vitale Flora, Martellucci Stefano, Conway Tara L., Chakraborty Sharmistha, Marampon Francesco, Mattei Vincenzo, Gravina Giovanni Luca, Biordi Assunta Leda, Wei Daoyan, Newman Robert A., Festuccia Claudio. Frontiers in Pharmacology.